Longitudinal tau PET as an Outcome Measure for Clinical Trials
tau PET imaging shows progression of brain Alzheimer’s pathology over time and correlates with cognitive impairment better than amyloid PET. In future clinical trials, tau PET can serve as a biomarker for Alzheimer’s disease progression.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.